Your browser doesn't support javascript.
loading
Monitoring Intrafraction Motion of the Prostate During Radiation Therapy: Suggested Practice Points From a Focused Review.
Shimomura, Aoi; Wu, Tianming; Rusu, Iris; Kishan, Amar U; Tree, Alison C; Solanki, Abhishek A; Liauw, Stanley L.
Afiliación
  • Shimomura A; Department of Radiation and Cellular Oncology, University of Chicago Medicine, Chicago, Illinois.
  • Wu T; Department of Radiation and Cellular Oncology, University of Chicago Medicine, Chicago, Illinois.
  • Rusu I; Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, Illinois.
  • Kishan AU; Department of Radiation Oncology, University of California, Los Angeles, California.
  • Tree AC; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Division of Radiotherapy and Imaging, Institute of Cancer Research, Sutton, United Kingdom.
  • Solanki AA; Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, Illinois.
  • Liauw SL; Department of Radiation and Cellular Oncology, University of Chicago Medicine, Chicago, Illinois. Electronic address: sliauw@uchicago.edu.
Pract Radiat Oncol ; 14(2): 146-153, 2024.
Article en En | MEDLINE | ID: mdl-37875222
ABSTRACT

PURPOSE:

External beam radiation therapy to the prostate is typically delivered after verification of prostatic position with image guidance. Prostate motion can occur during the delivery of each radiation treatment between the time of localization imaging and completion of treatment. The objective of this work is to review the literature on intrafraction motion (IFM) of the prostate during radiation therapy and offer clinical recommendations on management. METHODS AND MATERIALS A comprehensive literature review was conducted on prostate motion during prostate cancer radiation therapy. Information was organized around 3 key clinical questions, followed by an evidence-based recommendation.

RESULTS:

IFM of the prostate during radiation therapy is typically ≤3 mm and is unlikely to compromise prostate dosimetry to a clinically meaningful degree for men treated in a relatively short treatment duration with planning target volume (PTV) margins of ≥3 to 5 mm. IFM of 5 mm or more has been observed in up to ∼10% of treatment fractions, with limited dosimetric effect related to the infrequency of occurrence and longer fractionation of therapy. IFM can be monitored in continuous or discontinuous fashion with a variety of imaging platforms. Correction of IFM may have the greatest value when tighter PTV margins are desired (such as with stereotactic body radiation therapy or intraprostatic nodule boosting), ultrahypofractionated courses, or when treatment time exceeds several minutes.

CONCLUSIONS:

This focused review summarizes literature and provides practical recommendations regarding IFM in the treatment of prostate cancer with external beam radiation therapy.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Próstata / Neoplasias de la Próstata Límite: Humans / Male Idioma: En Revista: Pract Radiat Oncol Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Próstata / Neoplasias de la Próstata Límite: Humans / Male Idioma: En Revista: Pract Radiat Oncol Año: 2024 Tipo del documento: Article